MXPA04007681A - Sistema de liberacion. - Google Patents

Sistema de liberacion.

Info

Publication number
MXPA04007681A
MXPA04007681A MXPA04007681A MXPA04007681A MXPA04007681A MX PA04007681 A MXPA04007681 A MX PA04007681A MX PA04007681 A MXPA04007681 A MX PA04007681A MX PA04007681 A MXPA04007681 A MX PA04007681A MX PA04007681 A MXPA04007681 A MX PA04007681A
Authority
MX
Mexico
Prior art keywords
delivery system
vaginal cavity
internal phase
high internal
emulsion
Prior art date
Application number
MXPA04007681A
Other languages
English (en)
Inventor
Thomas C Riley
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of MXPA04007681A publication Critical patent/MXPA04007681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B2017/4216—Operations on uterus, e.g. endometrium

Abstract

Un sistema de liberacion farmaceutica que libera un agente activo de manera controlada durante un periodo prolongado en la cavidad vaginal, para tratar o curar aflicciones asociadas con la cavidad vaginal o areas proximas. El sistema de liberacion incluye un aplicador que esta compuesto de una emulsion de alta fase interna, permitiendo al sistema de liberacion adherirse a las superficies de las mucosas corporales, basicamente en la cavidad vaginal. El sistema de liberacion puede mantener la alta emulsion en fase interna a una temperatura de 30°C durante al menos un mes, sin descomposicion o inestabilidad de la emulsion.
MXPA04007681A 2004-07-08 2004-07-08 Sistema de liberacion. MXPA04007681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58627304P 2004-07-08 2004-07-08
PCT/US2004/022058 WO2006016869A1 (en) 2004-07-08 2004-07-08 Delivery system

Publications (1)

Publication Number Publication Date
MXPA04007681A true MXPA04007681A (es) 2006-01-12

Family

ID=35787422

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04007681A MXPA04007681A (es) 2004-07-08 2004-07-08 Sistema de liberacion.
MX2007000109A MX2007000109A (es) 2004-07-08 2005-07-08 Sistema de liberacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2007000109A MX2007000109A (es) 2004-07-08 2005-07-08 Sistema de liberacion.

Country Status (13)

Country Link
EP (1) EP1765452A4 (es)
CN (2) CN1771023A (es)
AU (2) AU2004100776A4 (es)
BR (1) BRPI0513066A (es)
CA (1) CA2572919A1 (es)
CZ (1) CZ15068U1 (es)
ES (1) ES1060042Y (es)
FR (1) FR2872702B3 (es)
MX (2) MXPA04007681A (es)
NL (1) NL1026978C1 (es)
NZ (1) NZ552406A (es)
RU (1) RU2379027C2 (es)
WO (2) WO2006016869A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2008651A1 (en) * 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
EP2100632A1 (en) 2008-03-11 2009-09-16 Pantarhei Devices B.V. Applicator device for body cavity
US8308678B2 (en) 2008-09-23 2012-11-13 Mcneil-Ppc, Inc. Pre-filled applicator device
EP2359750A1 (en) 2010-02-15 2011-08-24 Delphi Bioscience B.V. Screening device with valve
FR2968004B1 (fr) 2010-11-29 2013-06-28 Sojasun Technologies Films naturels biodegradables a base de co-produits issus de processus industriels de traitement de graines.
RU2538703C2 (ru) * 2013-03-12 2015-01-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения вагинального кандидоза и способ ее получения
CN108371746B (zh) * 2015-09-18 2021-01-05 宋殿芳 一种妇科的外用药防脱落的施药装置
JP2021526406A (ja) * 2018-06-11 2021-10-07 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 膣の状態を治療するための方法及びアプリケータ
CN109568130B (zh) * 2018-12-11 2021-02-05 管云 助力式配药器

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636202A (en) * 1984-07-27 1987-01-13 Syntex (U.S.A.) Inc. Medicament applicator with plunger assembly and automatically-openable closure therefor
US5266329A (en) * 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
ES2133090B1 (es) * 1997-02-21 2000-04-01 Uriach & Cia Sa J Nuevo aplicador para la administracion de medicaciones semisolidas.
US6403576B1 (en) * 1998-08-24 2002-06-11 The United States Of America As Represented By The Secretary Of The Navy Antifungal and antiparasitic compounds
US20040047910A1 (en) * 2000-07-07 2004-03-11 Christian Beckett Suppository and composition comprising at least one polyethylene glycol

Also Published As

Publication number Publication date
RU2379027C2 (ru) 2010-01-20
FR2872702A3 (fr) 2006-01-13
NL1026978C1 (nl) 2006-01-10
RU2007104782A (ru) 2008-08-20
CN102188375A (zh) 2011-09-21
WO2006016869A1 (en) 2006-02-16
CZ15068U1 (cs) 2005-01-31
NZ552406A (en) 2010-07-30
EP1765452A4 (en) 2012-11-28
WO2006014572A1 (en) 2006-02-09
CA2572919A1 (en) 2006-02-09
MX2007000109A (es) 2007-03-26
CN1771023A (zh) 2006-05-10
ES1060042U (es) 2005-07-16
AU2005269844A1 (en) 2006-02-09
AU2004100776A4 (en) 2004-11-18
EP1765452A1 (en) 2007-03-28
ES1060042Y (es) 2005-11-01
FR2872702B3 (fr) 2006-06-02
BRPI0513066A (pt) 2008-04-22

Similar Documents

Publication Publication Date Title
EP1765452A4 (en) SUPPLY SYSTEM
IL252715A0 (en) Combinations and forms of administration of therapeutic agents and combined treatment
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
PH12018502124A1 (en) Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR0014929A (pt) Dispositivo para distribuição de medicamento, e, processo para distribuir um agente farmaceuticamente ativo para um tecido alvo dentro de um corpo
BR0316157A (pt) Derivados de 4-amino-5-fenil-7-ciclohexil-pirrolo[2,3-d]pirimidina
WO2004064734A3 (en) Combination therapies for the treatment of cancer
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
RS20070076A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
BR112019006228A2 (pt) tratamento de câncer de próstata
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2007098479A3 (en) Localized insulin delivery for bone healing
RS20070077A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflamatory diseases
MY142098A (en) Delivery system
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
MX2021003030A (es) Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.
BR0317772A (pt) Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento
BRPI0509305A (pt) uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
AR028611A1 (es) Sistema terapcutico transcutrneo con reduccion de la tendencia a la cristalizacinn de sustancia activa
TH84091B (th) ระบบการส่งมอบ
JOP20180088B1 (ar) صيغ سائلة من (s)-n-(5-((r)-2-(2، 5-داي فلورو فينيل)-بيروليدين-1-يل)-بيرازولو[1، 5-a] بيريميدين-3-يل)-3-هيدروكسي بيروليدين-1-كربوكساميد
TH84091A (th) ระบบการส่งมอบ
CO5011086A1 (es) Budesonida sola o en combinacion con acido ursodesoxicolico en la terapia de enfermedades colestasicas del higado
HN1999000087A (es) Aparato dispensador de polvo seco y metodos de uso del mismo